Effect of repeated administration of KT3-671, a nonpeptide AT1 receptor antagonist, on diurnal variation in blood pressure, heart rate, and locomotor activity in stroke-prone spontaneously hypertensive rats as determined by radiotelemetry

Journal of Cardiovascular Pharmacology
K KawashimaA Tomiyama


KT3-671, a nonpeptide AT1 receptor antagonist, was administered to 20-week-old stroke-prone spontaneously hypertensive rats (SHRSP) daily for 3 weeks. Its effects on systolic, mean, and diastolic arterial blood pressure (SAP, MAP, DAP), heart rate and locomotor activity were investigated with radiotelemetry. A clear diurnal variation in blood pressure, heart rate, and locomotor activity was observed in synchrony with the light cycle. KT3-671 at a daily dose of 10 mg/kg orally (p.o), produced a significant and consistent reduction in blood pressure, preventing the development of hypertension. KT3-671 reduced SAP more than DAP, suggesting that it may affect both vascular tone and cardiac output. Although KT3-671 did not affect diurnal rhythms in heart rate and locomotor activity, it did cause a slight but significant reduction in heart rate. The MAP determined 23 h after the administration of KT3-671 showed a significant reduction from the day 2 of therapy to the day 3 after discontinuation of therapy, suggesting a long duration of antihypertensive action. There was no rebound increase in blood pressure after discontinuation of KT3-671 therapy. These results suggest that KT3-671 may be potentially useful in the therapy of hyperte...Continue Reading


Apr 1, 1991·Hypertension·N E RhalebD Regoli
Jan 1, 1982·Circulation·W T Friedewald, C D Furberg
Jul 1, 1980·Circulation Research·S WallensteinJ L Fleiss
Dec 1, 1993·Journal of Cardiovascular Pharmacology·M K BazilR L Webb
Jan 1, 1995·Journal of Cardiovascular Pharmacology·S MochizukiA Tomiyama
Sep 1, 1994·Japanese Journal of Pharmacology·T KatoM Sakanashi
Feb 1, 1993·Naunyn-Schmiedeberg's Archives of Pharmacology·J S ZhangP A Van Zwieten

❮ Previous
Next ❯


Oct 25, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Thomas CunninghamAlan Frazer
Oct 9, 1998·Clinical and Experimental Hypertension : CHE·R L WebbP Sahota
Dec 4, 2003·British Journal of Clinical Pharmacology·D PattersonT MacDonald
Jul 1, 1999·Addiction Biology·A K ChoY Kumagai
Feb 7, 2019·Clinical and Experimental Hypertension : CHE·Hiroshi KawamuraToru Nabika

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.